When the Food and Drug Administration (FDA) banned sales of all transvaginal mesh products for pelvic organ prolapse in April 2019, the ruling created a wave of confusion around a condition that’s often misunderstood.
Traditional repairs correcting pelvic organ prolapse have too often weakened over time and required revisional surgery. Based on promising initial data from a pilot study, we are studying whether the simple addition of vaginal estrogen might reduce the need for additional procedures in postmenopausal women.
